SYBX Synlogic (SYBX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001527599
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Synlogic insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SYNLOGIC, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Apr 2, 2025.
- The trade is 1.2% of the 12,744 shares held after it.
- No other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks below Dooley Mary Beth sold about $284 of SYBX on Oct 29, 2025.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 3, 2025.
- The trade is 1.1% of the 12,901 shares held after it.
- No other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks below Dooley Mary Beth sold about $173 of SYBX on Apr 2, 2025.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Oct 29, 2024.
- The trade is 16.2% of the 13,045 shares held after it.
- No other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks below Dooley Mary Beth sold about $2.8K of SYBX on Feb 3, 2025, the largest insider sale at the company since 2023.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 2, 2024.
- The trade is 0.5% of the 15,152 shares held after it.
- No other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of Finance Dooley Mary Beth sold about $111 of SYBX on Oct 29, 2024.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.2% of the 15,231 shares held after it.
- 1 other insider sold within 30 days.
- No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of Finance Dooley Mary Beth sold about $325 of SYBX on Apr 2, 2024, the largest insider sale at the company since 2023; 1 other insider sold within 30 days.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 94% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SYBX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-39.0%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SYBX: institutional holders (13F)
13F holdings, latest reported quarter
23,763 sh
$16.7K
Congress trades in SYBX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SYBX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SYBX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Large-Cap Growth Portfolio
$3.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
0 active
1
Phase 3
0 active
1
Early Phase 1
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
SYBX financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SYBX
| FY Dec 2025 | $0 |
| FY Dec 2024 | $8.0K |
| FY Dec 2023 | $3.4M |
| FY Dec 2022 | $1.2M |
| FY Dec 2021 | n/a |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM SYBX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -1,818% |
| FY Dec 2022 | -5,606% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$3.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SYBX
| FY Dec 2025 | -$4.4M |
| FY Dec 2024 | -$31.7M |
| FY Dec 2023 | -$51.8M |
| FY Dec 2022 | -$57.6M |
| FY Dec 2021 | -$52.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$923.0K |
| Sep 2025 | -$1.4M |
| Jun 2025 | -$399.0K |
| Mar 2025 | -$1.6M |
| Dec 2024 | -$568.0K |
| Sep 2024 | -$648.0K |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity SYBX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt SYBX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-5.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SYBX
| FY Dec 2025 | -8.2% |
| FY Dec 2024 | -102.6% |
| FY Dec 2023 | -106.2% |
| FY Dec 2022 | -57.6% |
| FY Dec 2021 | -46.2% |
| Jun 2026 | -5.3% |
| Mar 2026 | -5.0% |
| Dec 2025 | -8.2% |
| Sep 2025 | -27.5% |
| Jun 2025 | -8.1% |
| Mar 2025 | +22.8% |
| Dec 2024 | -102.6% |
| Sep 2024 | -145.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-4.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SYBX
| FY Dec 2025 | -5.7% |
| FY Dec 2024 | -49.0% |
| FY Dec 2023 | -65.7% |
| FY Dec 2022 | -46.3% |
| FY Dec 2021 | -38.0% |
| Jun 2026 | -4.2% |
| Mar 2026 | -3.9% |
| Dec 2025 | -5.7% |
| Sep 2025 | -17.3% |
| Jun 2025 | -5.3% |
| Mar 2025 | +9.5% |
| Dec 2024 | -49.0% |
| Sep 2024 | -94.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SYBX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-37.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SYBX
| FY Dec 2025 | -32.6% |
| FY Dec 2024 | -141.2% |
| FY Dec 2023 | -76.6% |
| FY Dec 2022 | -51.2% |
| FY Dec 2021 | -40.5% |
| Jun 2026 | -37.9% |
| Mar 2026 | -34.5% |
| Dec 2025 | -32.6% |
| Sep 2025 | -37.9% |
| Jun 2025 | -32.7% |
| Mar 2025 | -17.5% |
| Dec 2024 | -141.2% |
| Sep 2024 | -141.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SYBX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 5.90x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value SYBX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-29.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield SYBX
| FY Dec 2025 | -33.3% |
| FY Dec 2024 | -193.4% |
| FY Dec 2023 | -146.5% |
| FY Dec 2022 | -7.2% |
| FY Dec 2021 | -2.1% |
| Jun 2026 | -46.9% |
| Mar 2026 | -46.5% |
| Dec 2025 | -33.3% |
| Sep 2025 | -20.5% |
| Jun 2025 | -21.7% |
| Mar 2025 | -120.3% |
| Dec 2024 | -193.4% |
| Sep 2024 | -210.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SYBX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $8.0K | $3.4M | $1.2M |
| Operating income | -$4.0M | -$41.0M | -$55.2M | -$67.4M |
| Net income | -$1.0M | -$23.4M | -$61.3M | -$66.1M |
| EPS (diluted) | -0.08 | -1.92 | -9.42 | -13.83 |
| Operating cash flow | -$4.4M | -$31.7M | -$51.6M | -$56.9M |
| Cash | $14.7M | $18.9M | $24.0M | $15.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
SYBX Stock Sonar score 3/7 axes
Find similar shapesCompareSYBX ranks highest on profitability (73rd percentile) and risk and compliance (71st), and lowest on growth (1st), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
